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Abstract
Motor neuron disease (MND) is a progressive and fatal neuromuscular disease; 
the most common and severe form of MND presentation is amyotrophic lateral 
sclerosis (ALS), commonly known as Lou Gehrig’s disease. The majority of ALS 
patients die within 2–5 years of receiving a diagnosis. Familial ALS is a hereditary 
form of the disease and accounts for 5–10% of cases, whereas the remaining cases 
have no clearly defined etiology. ALS affects persons of all ethnicities and races; 
currently, no curative treatment for ALS is available worldwide. ALS is also the 
major adult-onset MND and is clinically, pathologically, and genetically associated 
with fronto-temporal dementia in some cases, which is the second cause of demen-
tia in elderly people. However, MND does not affect sphincter, sexual function, 
or eye movements. MND is the most common degenerative disorder affecting the 
upper and lower motor neurons at the same time. Most of the patients presenting 
MND in our series complained of muscle weakness, muscle wasting, fasciculation, 
and spasticity plus lower cranial nerve disturbances. According to our bibliographic 
studies, apart from nusinersen, it seems to be that riluzole and edaravone also 
improve motor neuron function by acting on SK channels.
Keywords: motor neuron disease, amyotrophic lateral sclerosis, spinal muscular 
atrophy, riluzole, edaravone
1. Introduction
Motor neuron disease is composed of a group of rare neurodegenerative disor-
ders, such as amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), 
hereditary spastic paraplegia, primary lateral sclerosis, progressive muscular 
atrophy, pseudobulbar palsy, O’Sullivan-McLeod syndrome, and Madras motor 
neuron disease, which are fatal in 50% of affected people within 15–20 months after 
diagnosis. MND is a progressive neuromuscular disease with a fatal outcome; the 
commonest clinical presentation of MND presentation is ALS, commonly known 
as Lou Gehrig’s disease. Most of ALS patients pass away within 2–5 years of con-
firmed a diagnosis. Familial ALS (ALSf) is a hereditary presentation of the disease 
and accounts for 5–10% of affected people. ALS affects persons of all ethnicities 
worldwide; no cure for ALS has yet been available at any country. Sometimes, 
ALS is clinically, pathologically, and genetically associated with fronto-temporal 
dementia, which is the second cause of dementia in elderly people. In our first book, 
we reviewed all previous chapters published by INTECH, and in the Introductory 
Chapter, readers could find summarized information about all publications on ALS 
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made by INTECH. Trying to illustrate the reached progress, we displayed this infor-
mation grouped by topics and countries in two graphics. As we saw on that book, 
the number of publications written about ALS increased remarkably for the past 4 
years. To have some idea of this phenomenon, be informed that INTECH published 
more than 40 chapters on ALS in this period of time, and these books “Amyotrophic 
Lateral Sclerosis,” “Current Advances on Amyotrophic Lateral Sclerosis,” and others 
are fully available on line, for free. Therefore, why we are going to publish another 
chapter? All novel information about MND were not published. Therefore, some 
aspects published in 2012 need to be update because new ideas, proposals, findings, 
experiences, and many other’s knowledge have been arising despite of this short 
period of time. Therefore, for the benefit of the readership community, we included 
update information not reported before, mainly new contribution of aberrant 
astrocytes to MND damage and death in the SOD1G93A rat experimental model of 
ALS; novel genetics studies on ALS; an update of the structural and functional con-
sequences of the spinal muscular atrophy-linked mutations of the survival motor 
neuron protein; stem cell therapy for MND; and the novel treatment for SMA and 
ALS in the introductory chapter of this book. Compromises have been inevitable to 
accommodate our visual and factual updated information in a book of his charac-
teristic on top of many chapters about the same issue published recently.
MND does not affect sphincter, sexual function, or eye movements [1]. 
Although ALS is not associated with thermoregulatory dysfunction, its progression 
can affect intensively important cerebral regions that control body temperature and 
affect multiple functions of this homeostatic activity. Nevertheless, experimental 
ALS animals can display altered thermoregulation as a consequence of affected 
energy homeostasis. Indirect evidence suggests, performing studies on the body 
temperature regulatory system, both as a possible modifier of disease progression in 
ALS and as a potential biomarker [2].
Although edaravone and riluzole do not cure MND/ALS, it seems to be that both 
medications can slow its progression. The prevalence of ALS in America was 5.2 
per 100,000 populations with a total of 16,583 cases identified from January 1 to 
December 31, 2015 [3].
MND is the most common degenerative disorder, which affects the upper and 
lower motor neurons at the same time. There are different clinical modalities of 
MND being ALS the commonest one, and its incidence is around 1–3 patients every 
100,000 people [4, 5].
The higher incidence of ALS is in patients with 60 and 70 years of age, but some 
younger cases (20–30 years of age) have been reported as well [4]. Between 5 and 
10% of the patients have a familiar origin due to Mendelian autosomal dominant 
transmission.
Most of the patients presenting MND in our series complain of muscle weak-
ness, muscle wasting, fasciculation, and spasticity plus cranial nerve disturbances 
from the lower brainstem.
The most frequent mutation seen in the familial form of ALS (ALSf) occurs on 
the gene of superoxide dismutase 1 (SOD1) and on the chromosome 9, among oth-
ers. The decreased endovascular factor and the hereditary hemochromatosis protein 
are also genetic mutations. Some variations in the number of copies of Genes 1 and 
2 that codify the motor neuron survival factors have been reported [6]. No correla-
tion investigations have been done. However, some genome-wide studies in patients 
presenting ALS show a series of loci confirming a greater susceptibility to develop 
the disease such as kinase carbohydrate (FGGY), dipeptidyl-peptidase 6 (DPP6), 
and Type 2 inositol triphosphate receptor [7–9]. Most of these findings were not 
able to be replicated in further investigations done. At present, there is not specific 
cure for this deadly disorder as was mentioned before.
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Long time ago, a nitrogenic expansion on the gene C9ORF72 was observed in a 
number of patients presenting ALS associated with Chromosome 9, which brought 
more clarity in the ethiopathogenesis of ALS [10, 11], but these findings are also 
seen in patients presenting fronto-temporal dementia (FTD) and ALS-FTD  
[10, 11]. Below, we will deliver more comments about this topic.
Future genetic investigations should be focused on non-European populations in 
order to bring more clarity on new pathogenic loci.
In the forthcoming years, the exome study that is an emerging field will bring 
novel information about some implicated genes in ALSf.
In 2018, Thompson et al. [12] used a high-throughput proteomic process to dis-
tinguish new biomarkers in patient’s cerebrospinal fluid (CSF), and they found that 
three macrophage-derived chitinases had increased concentration in ALS: chitin-
ase-3-like protein 1, chitotriosidase, and chitinase-3-like protein 2. Elevated CHI3L1 
was commonly seen in ALS, while CHI3L2 and CHIT1 levels did not. Their results 
confirmed the important role of macrophage activity in pathogenesis of ALS.
Decreased cough capacity is almost always present in respiratory tract infec-
tion and is the most important cause of respiratory failure in ALS patients. Other 
authors determined whether the lung function measurement could identify the 
cough function in ALS patients with respiratory tract infection. After screening 
48 patients presenting ALS, they found only four presenting a remarkable cough 
with no assistance. The data that identified unassisted cough effectiveness are peak 
cough flow. These investigators highlighted that the effectiveness of assisted and 
unassisted cough function depends on the peak cough flow reached [13].
It is well known that MND does not affect the motor neurons at the oculomotor 
nucleus in the midbrain. Because it could be remarkably advantageous if neurons 
of motor system resilience can be modeled in vitro, some authors reached elevated 
quantities of oculomotor neurons from embryonic stem cells in mouse through 
transient over expression of PHOX2A in nerve cell progenitors, and they con-
firmed, using immunocytochemistry techniques, electrophysiology studies, and 
RNA sequencing, that in vitro-generated neurons are bona fide oculomotor neuron 
cells based on their neuron properties and similarity to their counterpart in rodent 
(in vivo) and human beings [14].
Increased cortical excitability, thought to reflect pathological changes in the 
balance of local excitatory and inhibitory neuronal influences that are commonly 
seen in patients presenting ALS and non-invasive brain stimulation (NIBS), has 
been shown to modulate cortical activity, with some protocols showing effects that 
outlast the stimulation by months. Therefore, NIBS has been proposed as a probable 
candidate to approach therapeutically these disorders associated with pathological 
neurophysiology activity, such as ALS, among others [15].
ALS type 8 (ALS8) is a familial presentation of MND, with an important 
anterior horn cell degeneration, due to mutation of the vesicle-associated mem-
brane protein-associated protein B. Some authors compare the cognitive function 
of patients with ALS8 and a control group composed by healthy people in order 
to screen behavioral features in ALS8 patients. These authors found that ALS8 
patients showed minimal deficits in executive functions. The total amount of ALS8 
patients and the control group have the same scores of facial emotion recognition. 
They also determined an important clinical expression of psychiatric disorder such 
as anxiety and depression in 36 and 27% of patients, respectively. However, behav-
ioral disturbances were present in around 30% of participants. They concluded 
that these patients had mild executive problems and behavioral problems such as 
apathy, mood disorder, and stereotypic behavior, which suggest that ALS8 is not 
a motor disorder only, and it is associated with minor cognitive and behavioral 
changes [16].
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Because one of the most effective clinical strategies for SMA is to protect the 
anterior horn cell, apart from nusinersen (that is a very expensive medication), one 
anti-epileptic medication levetiracetam has been used as well.
Kepra (levetiracetam) provoked neurite elongation in SMA-iPSCs-MNs. 
TUNEL-positive anterior horn cell was significantly decreased by kepra in SMA-
iPSCs-MNs. On the other hand, the expression level of cleaved-caspase 3 was 
diminished by levetiracetam in SMA-iPSCs-MNs. Furthermore, kepra improved 
impaired mitochondrial function in SMA-iPSCs-MNs. On the other hand, kepra did 
not modify the expression level of SMN protein in SMA-iPSCs-MNs. These results 
suggest that kepra has a neuroprotective effect for SMA [17].
For patients presenting SMA (most common reason of inherited infant mortal-
ity), the gene therapy seems to be the most effective strategy [18].
Another therapeutic modality to treat ALS is the noninvasive brain stimulation 
(NIBS), which has been shown to modulate cortical activity, with some protocols 
leading effects that outlast the stimulation by months. NIBS have been suggested 
as a potential treatment choice in those processes with associated changes in the 
cortical neurophysiology [15].
A total of 25 genes associated with ALSf and ALS (sporadic form), mutations in 
fused-in-sarcoma (FUS) and superoxide dismutase 1 (SOD1) have been intensively 
studied in the past, focusing on modified excitability of motor neurons. Based on 
their personal experience, Peikkert et al. [19] proposed that the 4-aminopyridine 
(4-AP), which is a potassium channel blocker, can be utilized as a probable therapy 
for ALS patients due to its demonstrated hypo excitability and high frequency of 
apoptosis in a FUS/SOD1-ALS-induced multi-potent stem cell from selected motor 
neuron; they also found that this process is partly reversible by 4-AP.
One of the clinical presentations of MND is SMA, which encompasses a group 
of autosomal recessively inherited degenerative neuromuscular diseases. SMA is an 
inherited disorder that causes progressive lesions on the anterior horn cell leading 
to weakness or paralysis of the affected limbs, and it is caused by elimination or 
mutation of survival motor neuron (SMN) 1 gene. It is well known that homozy-
gous damage and loss of functional mutations in the survival motor neuron 1 gene 
(SMN1) at the chromosome 5q13 are the main cause of SMA, which affect 1 in 
11,000 newborn infants.
SMA usually has a very poor prognosis after rapidly progressive weakness and 
early mortality. However, a new medication named Nusinersen has been released 
for the treatment of all forms of SMA (not on mechanical ventilation) with very 
good results. In December 2016, this medication was approved in the United States. 
Nusinersen, an antisense oligonucleotide (ASO), is administered directly into CSF. It 
alters SMN2 pre-RNA splicing, so exon 7 is included, increasing expression of func-
tional SMN protein. Efficacy assessments for patients receiving nusinersen are based on 
serial assessments of performance on age-appropriate standardized motor scales. Treatment 
requires complex financial and logistics because of the very high drug cost, intrathecal 
administration, and medical fragility of the patients. Treatment implementation also 
engenders ethical considerations related to cost, insurance coverage, limited clinical data on 
groups of patients not in clinical trials, and questions of duration of treatment [20].
One in 50 asymptomatic people carries this autosomal recessive neuromuscular 
code causing SMA in one over 10,000 live births [21].
Based on age at onset, the highest milestone reached, and phenotypic severity: 
SMA has been separated into four different subgroups such as “Nonsitters” (Type I), 
“sitters” (Type II), “walkers” (Type III), and “adult onset” (Type IV) [22].
At the present moment, many patients got confirmation of diagnose very late, or 
the treatment is administered in advance stages. Therefore, poor response is often 
obtained.
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Fortunately, some screening programs are available and accurately and then to 
identify children in pre-symptomatic stages is possible [23]. However, because some 
children develop their clinical manifestation far from birth then to decide when to 
initiate the treatment and whom qualify for therapy is a dilemma.
The majority of SMN2 pre-mRNA transcripts undergo alternative splicing due to 
a nucleotide substitution leading to exclusion of exon 7. Degradation of the result-
ing truncated SMN protein is very fast, and the overall lack of full-length SMN 
protein causes permanent damage on anterior horn cell of the spinal cord [23].
In patients with onset of the disease beyond six months of age, large phase 3 
trials confirmed improvement in motor activities, very high event-free and remark-
able survival in infantile-onset SMA3, also significant improvement in Expanded 
version of the Hammersmith Functional Motor Scale scores has been recorded 
[24, 25].
The copy number of the homologous SMN2 gene is inversely correlated with 
SMA severity and encoded by SMN1 (except for lack of exon 7), which is identical 
to the cDNA encoded by SMN2.
Currently, for the therapy of SMA, there are pipelines developed by antisense 
oligonucleotide (ASO), also available for Huntington disease, ALS, spinocerebellar 
ataxias, Parkinson disease, and Alzheimer disease, among other options, and the 
pharmaceutical industry on ASO development has been delivering a promising 
therapeutic approach. The key care concern to MND patients has been developed, 
and expert consensus guidelines delivered, and best management for lung diseases, 
nutritional problems, and palliative care has also been reached. However, in this 
chapter, we will discuss novel aspects related to treatment and other therapeutic 
procedures later on.
In pre-symptomatic SMA patient’s Types I–III released interim results of a phase 
2 trial evaluating the effects of Nusinersen have been done [23].
Some investigators have been working on stage of improvement after the treat-
ment of SMA and confirmed that the first published data supported important 
good results on the motor function and quality of life from animal models with 
early restoration of SMN levels for those studied within the first 3 postnatal days. 
However, for those treated beyond 5 postnatal days, the level of recovery was low, 
while delivered treatment after 10 postnatal days, it showed no improvement and 
died [26].
One of the problems found in our preliminary review is the big number of SMA 
patients diagnosed at late stage. We found Type I patient with 4 months after onset 
and Type III with 10 months or more after onset [27, 28].
However, newborn screening programs have been a successful process for 
identifying affected children at an asymptomatic stage, leading to pre-symptomatic 
initiation of treatment before irreversible anterior horn cell lesion appears. To per-
form screening methods before birth are certain, and they available and willing to 
deliver the possibility of distinguish patients at the beginning of pregnancy, giving 
a chance to perform a prenatal therapeutic management.
Taiwan and Belgium, also have screening programs for SMA, but in America, 
the leader and an important number of states, further clinical trials have been 
implemented to evaluate the applicability and economic advantages. Unfortunately, 
around 5% of mutations in the SMN1 cannot de identified [23].
Chorionic villus sampling or amniocentesis to identify children with higher risk 
for SMA with an elevated percentage of accuracy can be done, if it is performed 
during the 10–14 or 15–20 weeks of pregnancy. These procedures can be dangerous 
for the mother and the baby to be done in high-risk pregnancies with proven carrier 
status of the parents recommended [23]. Nevertheless, isolating circulating fetal tro-
phoblastic cells by noninvasive prenatal diagnosis techniques is also possible [29] or 
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even getting from maternal blood cell-free fetal DNA [30]. These above-mentioned 
techniques allow to identify SMA in unborn children with 100% accuracy, promis-
ing a better future for SMA patients [23].
At this stage, it is also important to mention that significant ethical issues are 
involved in this genetic screening methodology and its need to be considered by 
the medical community before making these procedures fully available [31]. At the 
present moment, we are not quite sure how to predict disease severity accurately 
or even its presence because not all patients present clinical manifestation birth 
or because only few minimal sings are detectable. Treatment algorithm for SMA 
patients confirmed by newborn screening based on SMN1 deletion analysis in 
dried blood spots is available since 2005 [28]. Indications of treatment are based on 
the clinical phenotype of the patients and correlation of SMN2 copy numbers. All 
patients presenting 2–3 copies should be treated with the immediate effect accord-
ing to NBS Multidisciplinary Working Group recommendations even if the child is 
asymptomatic with only one copy, but when four or more copies are present due to 
milder course of the disease, the treatment must be delayed [28].
In 2017, some authors studied a big number of SMA patients (n = 3500) trying to 
compare SMN2 copy number with their clinical information and found that patients 
with 1–4 copies have mild to severe phenotype, respectively, while there was an 
important overlap among patients with 2–3, confirming any possible phenotype 
[32], but more than 80% of patients in this group cohort carried two to three 
SMN2 copies, suggesting the similar problem in medical practice. In these cases, 
presenting two or three SMN2 copies to predict the severity of the disorder is not 
certain [23].
It is important to take into account that those SMA patients (families and 
siblings) presenting the same amount of SMN2 copies have another phenotype 
[33]; in the context, SMN1 (homozygous) mutations, SMN2 copies in people free 
of symptoms and signs, and even in SMA Type I have been found [34]. SMN2 
transcripts and the SMN2 copy number do not show any correlation in a series of 
investigations done between 2001 and 2017 [35–38].
Following some recommendations delivered by the Phase 1 trial and studies on 
its pharmacological process, the investigators found that the half-life of nusinersen 
in the CFS is 163 days, and the ideal way for administration should be intrathecal 
(at the dosage of 12 mg) every 4 months. After that period of time, patients should 
receive five intrathecal injections within the first 6 months of treatment. These 
authors also confirmed that no correlation exits between concentrations of the CSF, 
age of the patients, and body weight [39, 40].
Based on results published by Luu et al., the doses of nusinersen according to 
the age of the patients produce more median exposures in the CSF, which suggest 
that prescribing fixed dosage programs through all age groups is the best choice 
[40]. For the other hand, Finkel et al. [41] conducted a Phase 2 dose-escalation 
investigation confirming that a single dose of 12 mg is better than 6 mg. The best 
way to assess the outcome for these patients is to measure the advantage of motor 
milestone, depending on ventilator machine, achievement of motor activities, clini-
cal electrophysiological studies, and overall survival. Twenty patients younger than 
1 year of age and less than 10 kg of body weight were screened, and these results 
confirmed the previous postulate [41]. The results from the small group studied in 
phase 2 clinical trials and the pharmacological studies done can accurately reflect 
clinical practice, is an interrogation still no responded.
Taking into account the great variability among SMA patients related to the age 
at disease onset, residual motor function, body weight, and fixed dose at the same 
intervals for patients, it seems to be remarkably inaccurate [23]. Reliable biomark-
ers and screening procedures for proper diagnosis at early stage of the disease are 
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need more than ever if we are looking for longer survival and positive modifications 
of the patient outcome. If reliable biomarkers are not available, then determining 
the SMN protein level and epigenetic modifiers to provide confident information 
about the intensity of the process is mandatory. When more than three SMN2 copies 
are detectable, chance for life-saving treatment is not certain. In summary, novel 
screening techniques, procedures to predict the intensity of the disease, and reliable 
biomarkers, which support monitoring of the treatment, have been discovered 
and recently developed, but unfortunately, none of them provide an unequivocal 
explanation of the pathophysiology of SMA [23].
To develop more accurate diagnostic procedures including confident biomark-
ers, better therapeutic approaches, and novel predictors to determine the ideal 
dosing recommendation, more investigations are required. This is the only way to 
guarantee a reliable long-term treatment and successful outcome [23].
Two years ago, the European Medicines Agency finally approved nusinersen an 
antisense oligonucleotide (ASO) as the treatment of choice for SMA, and later, this 
medication has been considered as part of the treatment for patients with Type 2 
SMA as well [23]. In patients with SMA presenting spinal bone deformities, severe 
contractures, scoliosis, spine fusion surgeries, and respiratory distress, the adminis-
tration intrathecal of nusinersen could be a great challenge.
Recently, with the intention of assess, the accuracy, and feasibility of nusinersen 
administrated by lumbar puncture (LP) in young patients, Wurster et al. [42] 
studied in 93 patients in whom the LP is done, highlighting the amount of attempts 
performed, site of injection, length of the spinal needle, duration of the procedure, 
medications used for sedative purposes, local anesthesia, level of O2 saturation in 
blood, appearance of the CFS, and adverse effects. These results confirm that LP 
is the best way to administer this medication in adolescent and young adults with 
later-onset SMA even in candidates with spinal bone deformities and respiratory 
failure mainly if the patient is managed under a multidisciplinary team.
Nusinersen is not available in Africa as yet but can be found in many European 
countries for all SMA types.
A few weeks ago, Sansone et al. [43] reported their experience and good results 
after studied 50 SMA patients treated with intrathecal nusinersen. They concluded 
that in spite of the severity of the disease and the age of patients, this treatment 
is feasible, safe, and suitable for SMA patients if they are managed by a good 
skilled team.
According to the information provided by Gidaro et al., a few weeks ago, in 
Australia, the commercial availability of the medication from the transition of 
expanded access programmed its right in corner. While in New Zealand, a broad 
access to this program is available, and in Canada, negotiators are discussing about 
the most convenient price at the present moment. However, some problems such as 
advanced age, patients with respiratory failure depending ventilator machine, and 
patients presenting spinal fusion still need to be solved [44].
As was mentioned before, the traditional LP for intrathecal administration of 
nusinersen can be impeded due to deformities of the spinal bone and orthopedic 
surgical procedures among other impediments commonly seen in SMA patients. 
However, the accumulated experiences from cervical myelograms serve to recom-
mend this procedure as an ideal approach for cervical intrathecal administration of 
nusinersen, especially if it can be guided by ultrasound [45]. The same investigators 
studied 14 patients after the administration of nusinersen by cervical punctured 
guide by ultrasound with local anesthesia and found that all patients presented 
no major complications. One of the advantages of this technique is that general 
anesthesia is no required, and patients can be managed in real-time ultrasound 
guidance.
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The most significant advantage to antisense oligonucleotide (ASO) therapeutics 
over other small molecule approaches is that acquisition of the target sequence 
provides immediate knowledge of putative complementary oligonucleotide 
therapeutics.
In 2019, Scoles et al. [46] described several therapeutic modalities with ASO 
and how they can be indicated for medical treatment of SMA, apart from the work 
done to develop novel ASO therapies looking for better results in the management 
of neurodegenerative disorders [46]. Novel advances of the genetic studies will 
allow distinguishing different genetic information for many neurological disorders. 
The mutated protein found and its chance to be placing into the cellular pathway 
will support a faster development of way for treatment. For the other hands, new 
opportunities for reliable treatment have been arising from the new capacities 
of targeting the disorder gene and RNAs. Among other procedures, to target the 
expression of RNA, some authors highlighted the utilization of ASOs to treat 
neurological problems. Treatment based on ASOs varies from 18 to 30 base pairs in 
length. These investigators changed expression of a target mRNA modifying splic-
ing or by recruiting RNase H (cellular enzyme) that recognizes DNA: RNA hybrids 
causing target degradation [46].
Apart from nursinersen, other ASO therapeutics approved by FDA are eteplirsen 
to treat Duchene muscular dystrophy 2 and inotersen for managing patients pre-
senting familial amyloid polyneuropathy. For treatment of Huntington disease, 
ASOs targeting HTT have been used [47]. As we and other authors reported in other 
publications, the treatment of choices for ALS is SOD1 and C9ORF72 [48, 49] and 
MAPT (TAU) in cases affected by Alzheimer disease [50]. Because most of the 
treatment with ASO does not cross the blood-brain barrier (BBB), it is necessary to 
administer it by injection into the intraventricular system in mouse and by intrathe-
cal administration in humans.
Some investigators have mentioned that nucleic acids are prompt to nuclease 
degradation, and its protein binding is weak, leading to inefficient tissue uptake and 
unreliable use as drugs [26, 51].
Most of these changes modify the pharmacokinetic, pharmacodynamic, or 
endocytic uptake that controls the specific function of the proteins (cell surface) 
[51, 52].
Oligonucleotide chemistry, methoxyethyl oligonucleotide, constrained nucleic 
acids, Stereopure PS ASOs, Peptide nucleic acid, 5′-methylcytosine modification, 
target fate, mixed chemistry, and gapmers are aspects that are not discussed in this 
chapter and should be considered by interested readers on this matter. In order to 
get most complete information about it, we recommend checking the article of 
Scoles et al. [46].
ASOs are being used for some genetic etiology of ALS. Obviously, these biologi-
cal pathways affecting the recognized mechanism of production of the disorder also 
modify the results when ASO is used [53].
2. Therapy with riluzole and edaravone
In 1994, the idea about the role of the excitatory amino acid neurotransmit-
ter glutamate in the mechanism of production of ALS was prevalent. At that 
time, some investigators evaluated the safety and accuracy of the antiglutamate 
agent riluzole, at the dose of 100 mg daily, in patients presenting ALS. They 
studied 155 outpatients, and after 12 months of treatment, they found that 74% 
of the patients were still alive (P = 0.014), and the decrease of muscle power 
was remarkable in patients consuming riluzole compared with the control group 
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(placebo). Therefore, they concluded that riluzole decreases the speed of progres-
sion in ALS patients, and it can prolong the survival period in patients presenting 
bulbar palsy [54].
Without doubt, nusinersen improves motor neuron function, but riluzole by 
acting on SK channels also causes similar results [55].
Since 1996, it is well known that one of the etiological pathogenesis of ALS is 
caused by neural damage due to glutamate excite-toxicity. Riluzole is a synthetic 
benzothiazole drug with glutamine antagonist activity [56, 57].
The first analyses, and at posteriori meta-analyses done on results obtained 
from controlled trials by randomization, confirm that riluzole extends survival by 
2–3 months and augment the possibilities of an additional 12 months of survival by 
~9%. Same authors reported improvements in media survival times over 76 weeks 
for an important number of ALS patients [58].
In 1995, oral riluzole was approved by FDA as part of the treatment of 
ALS. Riluzole is a well-known presynaptic glutamate release inhibitor, which can 
provide neural injury and prevent muscle-power worsening. Currently, this medi-
cation has been licensed to be prescribed in many places including the European 
Union [59].
The dose of 50 mg twice, to be taken 1 hour before meal or 2 hours after it, has 
been approved by the Institute for Health and Care Excellence since 2001 with good 
results [60].
One good news is that riluzole is now available in oral suspension (Teglutik®) 
which presentation (5 mg/ml) and has been shown its beneficial for patients 
presenting bulbar palsy with functional dysphagia allowing longer therapy [61, 62].
Not randomized controlled trials (RCTs) with riluzole for ALS patients have 
been performed.
However, other RCTs have been done for patients with cervical myelopathy, 
chronic psychosis, and autistic spectrum disorder [63–65].
Real-world evidence confirmed that an important prolongation of median 
survival times in ALS patients treated with riluzole is certain. Based on retrospec-
tive/prospective investigations done on large database, these authors concluded that 
patients under riluzole therapy had better prognosis than those without treatment, 
mainly at the first stage of the pathological process [58].
Brooks et al. studied two series of ALS patients: one group of 51 patients under 
riluzole treatment and another group of 241 patients without riluzole (before 1996) 
and a second series of 112 ALS patients’ riluzole-treated and 65 nontreated patients 
(after 1996). These authors found that Cox analysis concluded that patients on 
treatment got an extension of survival (P < 0.0001) and even remarkable improve-
ments in elderly people and patients in advanced stage. Therapy with riluzole pro-
vides a median extension of survival in affected patients between 40 and 72 weeks 
[66]. Survival benefit would be 36 weeks if patients are managed like prospective 
RCTs according to other researchers [67]. Based on Cox model technique, Mitchell 
et al. found that survival times are bigger in riluzole-treated ALS patients than 
nontreated cases (HR 0.20, P < 0.001) [68]. While other authors communicated 
that Cox multivariate analysis of therapy was related to a prolongation of survival at 
48 weeks (HR 0.51, P = 0.06) [69].
Retrospective population-based studies on the effect of riluzole on survival 
of ALS patients done between 1999 and 2008 and made by Lee et al. concluded 
that Cox multivariate analysis (n = 1149) that riluzole provide a longer survival 
on treated-patients; unadjusted HR 0.32 (P < 0.001) and adjusted HR 0.34 
(P < 0.001) [70].
Georgoulopoulou et al. and Knibb et al. conducted a prospective population-
based study on the survival of 193 patients (between 2000 and 2009) and 575 cases 
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(between 1990 and 2013) consuming riluzole, respectively. According to the Cox 
multivariate model used during the first series of participants riluzole-treated, they 
reached a prolonged survival and remarkable delay of pulmonary complications 
including patients with bulbar palsy and even those with affected four limbs, and 
the second series of cases riluzole-treated showed a slower progression to pulmo-
nary involvement [71, 72].
Chen et al. also studied a group of ALS patients using the same methodol-
ogy and concluded that the median survival time in cases riluzole-treated was 
268 weeks compared to 256 weeks in nontreated cases (log-rank P = 0.780); HR 
0.855 (P = 0.167) [73].
Based on meta-analysis of RCTs recently done and all data obtained up to date, 
riluzole prolonged survival in ALS cases by 8–12 weeks and augmented the chance 
of additional 52 weeks of survival by ~9%.
Other authors reported that riluzole-treated cases can increase their median 
survival by up to 76 weeks, after reviewing 10 clinical ALS databases with around 
~6000 cases [58].
In a series of patients studied by Inoue-Shibui et al., riluzole therapy was inter-
rupted in 20 cases among 92 patients [74]. The most common cause of discontinu-
ation of riluzole was abnormal of liver enzymes (5.4%), followed by interstitial 
pneumonia, among other causes.
All adverse events happened within 24 weeks of the beginning of riluzole 
therapy, with 50% of the adverse events occurring within 2 weeks. In almost all 
patients, adverse events disappeared after stopping the treatment. In the real-
world setting, riluzole has been well assimilated for long periods of up to 7 years or 
more [75].
Recently, two patients presenting recurrent pancreatitis were communicated 
to the medical literature. In both cases, the diagnosis was done within the first 3 
months after initiated the treatment with riluzole [76], being another strong reason 
to highlight our recommendation about a careful observation of adverse events in 
the first 6 months of riluzole administration.
A few weeks ago, Jaiswal et al. also confirmed that riluzole delay progres-
sion of ALS in animal model based on their experiences and many experimental 
drug trials done over the past decades, but riluzole did not show similar results 
in human beings or results are still nonconcluded under Phase I–III trials, which 
are quite true, and riluzole is the only available medication with some benefits on 
survival [77]. Nevertheless, an antioxidant drug (edaravone) has been produced by 
Mitsubishi Tanabe Pharma, and its effectiveness in halting ALS progression during 
early stages has been found.
In 2015, edaravone (Ridicut) was launched for the management of patients 
with ischemic stroke at first and later for the treatment of ALS patients [78]. 
Edaravone is a drug with a free radical scavenger with no remarkable benefits in 
ALS patients according to Phase III clinical trial, but edaravone is also a strong 
antioxidant able to prevent oxidative stress leading to motor neuron fatal damage 
in ALS. These investigators found another study, which confirmed good therapeu-
tic response to edaravone in diagnosed patients by revised diagnostic criteria (El 
Escorial) of MND/ALS. Other authors investigated the effect of intraperitoneal 
administration of edaravone in wobbler’s mice and demonstrated that elevated 
dose (10 mg/kg) of edaravone therapy remarkable attenuated paresis and muscle 
contracture on the extremities and stopped denervation atrophy in the proximal 
muscles and degeneration in the cervical anterior horn cell neurons compared 
to control group. After large waiting period of 22 years, the Mitsubishi Tanabe 
Pharma America acquired an US FDA approval for edaravone (Radicava) in May 
2017 for the therapeutic approach of ALS.
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To low progression of MND/ALS, edaravone is a good indication according to 
the previous reports delivered to the medical literature. Recent phase three studies 
done on ALS patients treated with this medication did not confirm remarkable 
advantage in the Revised ALS Functional Rating score over the control group 
[79]. Between November 28, 2011 and September 3, 2014, the Writing Group 
[80] studied 213 cases and selected 192 candidates. Of these, 137 cases completed 
the first period for close observation: 69 were selected to be edaravone-treated 
(randomly), and 68 were assigned to control group to be treated with placebo 
also randomly, both series were included in the primary efficacy analysis. The 
results observed from the primary outcome demonstrated that the control group 
change −7.50 (0.66) in ALSFRS-R score compare with −5.01 (SE 0.64) in the group 
edaravone-treated. In favor of edaravone, the least-square mean confirmed a 
difference among two series of 2.49 (SE 0.76, 95% CI 0.99–33: P = 0.0013). These 
researchers concluded that edaravone works in a small subset of ALS patients 
who met criteria identified in post-hoc analysis of most recent Phase 3 studies, 
showing a remarkable diminish ALSFRS-R score compared with control group 
who received placebo. They also highlighted that there is no proof that edaravone 
might be efficient in a bigger series of ALS cases who do not meet the criteria [80]. 
The best way to administer edaravone (60 mg) is by slow IV infusion (2 hours 
duration) every 28 days. Edaravone has demonstrated its capacity to slow down 
the process of loss of motor function by 33% of ALS cases compared with control 
group. Being a powerful free radical scavenger, edaravone is able to inhibit nitration 
of tyrosine in the CSF and to improve the motor neuron cell activity in ALS mouse 
[81]. Unfortunately, there is no unanimous agreement about the positive effect of 
riluzole in patients presenting degenerative disorders. At the present moment, most 
of the neurology community agrees that riluzole is not a remarkable strong effect on 
the progression of ALS. Because the oxidative stress is considered to be involved in 
the pathology of ALS, almost all consider that the free radical scavenger edaravone 
may play a better relevant role for the treatment of cases presenting ALS. Without 
doubt, the first medication able to provide an efficient inhibition of motor neuron 
function deterioration in MND/ALS cases is edaravone if it is taken at early stage 
of this pathological disorder, but the lung function must be well assessed when a 
deterioration in the respiratory capacity is confirmed [82]. Most reports published 
in the medical literature show controversial benefits and safety about the edaravone 
treatment of ALS. Recently, Luo et al. [83] made a meta-analysis research to evalu-
ate the accuracy and safety of edaravone as a therapy of choice for ALS, by search-
ing PubMed, the Cochrane Library, and Embase from the inception of electronic 
data (April 2018), including randomized, double-blind, placebo-controlled trials 
reporting ALS cases receiving 60-mg IV edaravone or IV saline solution as placebo 
for 24 weeks. The study included 367 patients from three randomized controlled 
trials (183 patients on IV edaravone; 184 receiving IV saline solution). They arrived 
to the following conclusion: edaravone IV is a good treatment for ALS cases, with no 
remarkable side effects [83].
3. Other medications for MND
Although there is no available medicine to cure any clinical presentation of 
MND, during the first semester of this year (2019), a number of medications have 
been used to treat affected patients. Unfortunately, no remarkable results have been 
obtained, but some of them still show good action over this disease. In this chapter, 
we will deliver some comments about the results reached by some authors accord-
ing to their report to the medical literature. The most common used medications 
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are EH301, 5Fluoroucil, Tryptophan, RNS60, Rasagiline, Tirasemtiv, Aquaporin, 
Fasudil, and Lunasil.
de la Rubia et al. [84] evaluated the accuracy and feasibility of Elysium Health’s 
candidate drug EH301 in ALS cases by a single-center, prospective, double-blind, 
randomized, placebo-controlled pilot study. Thirty-two ALS patients studied 
underwent for assessment during 4 months. Differences between EH301 and con-
trol group were evaluated based on their findings, and EH301 confirmed a remark-
able slow progression of ALS compared with nontreated cases and even confirmed 
clinical benefits in many key outcome measures relative to their baseline.
Searching for drug candidates for ALS, Rando et al. investigated the action of 
anti-metabolite 5-fluorouracil (5-FU) administered by a single intraperitoneal 
injection at 150 mg/kg in SOD1G93A model of ALS. Un expectedly, the authors 
found that 5-FU (anti-cancer drug) increases survival delays of the disorder onset 
and improves motor function in ALS mice, but they were not able to demonstrate 
the mechanism of the beneficial 5-FU action in ALS mice. Despite of 5-FU did not 
improve the modulate motor neuron survival remarkably and did not improve 
reactive gliosis or change the muscle morphology, their findings recommended that 
a low dose of 5-FU or its analogs may have good effects on MND/ALS [85].
Other authors postulate that toxic gain of function, spread, and SOD1 misfold-
ing is suggested as part of pathological mechanism of MND/ALS, but the nature of 
SOD1 toxicity has been hard to describe [86]. Only in SOD1 proteins from humans 
and other primates, and rarely in other species, a tryptophan residue at position 32 
(W32) is predicted to be solvent exposed and to participate in SOD1 misfolding. 
DuVal et al. considered that W32 is influential in SOD1 acquiring toxicity, as it is 
known to be important in template-directed misfolding [86].
DuVal et al. highlighted the relevant influence of W32 on cases SOD1 toxicity to 
upper and lower motor neuron cells morphology and its activities. They assessed 
pharmaceutical targeting of the W32 residue for rescuing SOD1 toxicity [86]. 
When RNS60 is administered by IV infusion every 7 days and daily nebulization, it 
acts as a novel immune-modulator agent able to provide neuroprotective action in 
MND/ALS preclinical models. Paganoni et al. [87] studied 16 ALS patients during 
23 weeks for safety and tolerability. Some investigations were done such as PBR28 
positron emission tomography imaging and plasma biomarkers of inflammation. 
These authors did not find serious reactions, and no participants were removed 
from the study due to drug-related complications. At the present moment, a large, 
multicenter, Phase II trial of RNS60 is currently including cases to test the effects of 
RNS60 on MND/ALS biomarkers and disease deterioration based on the previous 
findings. They concluded that long-term RNS60 administered by IV infusion (as 
indicated) is well assimilated by patients and is also accurate [87]. In ALS, the pro-
long use of immune-modulating therapies has been showing not good results and 
did not help to understand how the immune system modifies disease outcome [88].
Rasagiline (monoamine oxidase B inhibitor) administered at 2 mg/day has 
a neuroprotective effect in MNS/ALS cases. In order to verify this postulate, 
Fernandez et al. performed a trial of 80 ALS patients from 10 hospitals in America. 
They did not identify any difference between Rasagiline-treated cases and the 
control group. Therefore, they assumed that Rasagiline did not change disease 
output compared with control group during 12 months of therapy. Rasagiline was 
well assimilated, and no serious adverse events were report.
Shefner et al. conducted a multinational clinical trial to study the accuracy of 
tirasemtiv (125 mg twice daily) using an escalating dosage protocol during 4 weeks 
[89]. Comparisons between two series of cases with ALS were performed. One 
group constituted by fast skeletal muscle troponin activator and a second control 
group by placebo. Of 744 candidates, 565 participants assimilated open-label 
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tirasemtiv and were treated randomly. As a side effect of tirasemtiv, nausea, weight 
loss, dizziness, fatigue, and insomnia were more often seen. The frequency of 
severe side effects was seen equally on both series of cases. Obviously, tirasemtiv 
did not change the decline of slow vital capacity or remarkable impact secondary 
outcome assessment and weak tolerability of tirasemtiv may lead to poor effect on 
MND/ALS.
Aquaporin 4 (AQP4) is present in astrocytes in the nervous system as primary 
water channel and has been postulated to participate in a myriad of acute, chronic 
brain disorders and the incidence of MND/ALS. Depolarization of AQP4 causes 
degeneration of the upper and lower motor neurons via GLT-1, and suppressions 
increase recovery of motor activity in MND/ALS cases probable due to NGF. No 
clinical trial targeting AQP4 has been done up to date [90].
Studies made with Fasudil (30 mg for IV application) have shown good results 
in cell culture and animal research of MND/ALS. This medication is a Rho kinase 
(ROCK) inhibitor, which has been used in Japan (1995) for the management of 
Reynaud’s syndrome, pulmonary hypertension, and vasospasm secondary to 
subarachnoid hemorrhage, angina pectoris, and also to treat complications from 
high blood pressure. Currently, some authors are looking for efficacy, safety and 
tolerability of a ROCK-ALS of fasudil in MND/ALS cases that started patient 
recruitment in 2019 [91]. ROCK (serine/threonine kinase) is a novel medication 
to target for neurodegenerative brain disorders, and it has two isoforms: ROCK1 is 
mainly for the peripheral nervous system, and ROCK2 is expressed preferentially in 
nervous central system [92]. Levels of ROCK augment according to age and tissue 
of MND/ALS cases. Some authors also confirmed increased levels of ROCK2 and 
downstream targets LIMK1 and coiling [93]. Fasudil also modifies microglia activity 
[91]. Main side effect of fasudil is intraparenchymal hemorrhage. Nevertheless, in 
studied population of cases with subarachnoid hemorrhage, the incidence of bleed-
ing did not differ remarkably from the control group. Therefore, hemorrhage is 
not an expected complication, and it will not put in risk the life in selected patient. 
Cases with past medical history of intraparenchymal bleeding, congenital or acquire 
aneurysms or Moyamoya disease should not be included in the therapeutic group.
Lingor et al. confirmed that ROCK-MND/ALS clinical trial provides a well-
tolerated, safe, and accurate way of treatment. The biomarker collection associated 
with this study will deliver additional data as indicators of progression. Finally, 
we comment about Lunasin a soy peptide that modify histone acetylation in vitro 
joined to single MND/ALS effect but no remarkable activity on histone acetylation or 
disorder deterioration in 50 participants treated during 5.5 months by Bedlack et al. 
[94]. Excellent retention and adherence have been found but not better results than 
riluzole or edaravone.
As a result of the great interest showed by investigators and participants on 
different studies done during the first half of this year (2019), today we can see an 
important number of other therapeutic procedures also looking for the best man-
agement of ALS patients. This modality ranges from physical exercises to acupunc-
ture including other choices such as stem cell therapy, treatment for sialorrhea, and 
spasticity, among others.
In our times, many healthy people do physical exercises on regular basis; some 
do exercise for slimming purposes, others for prophylactic treatment, rehabilita-
tion, and so forth.
Unfortunately, due to lack of space, these topics will not be included in this 
chapter.
After reviewing the most recent studies published in the medical literature, we 
concluded that we still have no curative treatment for MND patients, but a promis-
ing future is forthcoming.
Novel Aspects on Motor Neuron Disease
14
Author details
Humberto Foyaca Sibat* and Lourdes de Fátima Ibañez Valdés
Department of Neurology, Faculty of Health Sciences, Nelson Mandela Academic 
Central Hospital, Walter Sisulu University, Mthatha, South Africa
*Address all correspondence to: humbertofoyacasibat@gmail.com
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
15
Introduction to Novel Motor Neuron Disease
DOI: http://dx.doi.org/10.5772/intechopen.91921
References
[1] Foyaca Sibat H, de Fátima Ibañez 
Valdés L. Chapter I. Introduction 
to update in amyotrophic lateral 
sclerosis and review of this condition 
in sportsmen. Update in Amyotrophic 
Lateral Sclerosis. In: Sibat HF, editor. 




[2] Dupuis L, Petersen Å, Weydt P. 
Thermoregulation in amyotrophic 
lateral sclerosis. Handbook of Clinical 
Neurology. 2018;157:749-760. DOI: 
10.1016/B978-0-444-64074-1.00046-X
[3] Mehta P, Kaye W, Raymond J, 
Punjani R, Larson T, Cohen J, et al. 
Prevalence of amyotrophic lateral 
sclerosis—United States, 2015. 
Morbidity and Mortality Weekly Report. 
2018;67(46):1285-1289. DOI: 10.15585/
mmwr.mm6746a1
[4] Lopez-Vega JM, Calleja J, 
Combarros O, Polo JM, Berciano J. 
Motor neuron disease in Cantabria. Acta 
Neurologica Scandinavica. 1988;77:1-5
[5] Zarranz JJ. Neurología. 4th ed. 
Madrid: Elsevier; 2008
[6] Amato A, Russell J. Neuromuscular 
Disorders. McGrawHill: China; 2008
[7] Dunckley T, Huentelman MJ, 
Craig DW, Pearson JV, Szelinger S, 
Joshipura K, et al. Whole-genome 
analysis of sporadic amyo-trophic lateral 
sclerosis. The New England Journal of 
Medicine. 2007;357:775-788
[8] Van Es MA, van Vught PW, 
Blauw HM, Franke L, Saris CG, van 
Den BL, et al. Genetic variation in 
DPP6 is associatedwith susceptibility 
to amyotrophic lateral sclerosis. Nature 
Genetics. 2008;40:29-31
[9] Van Es MA, van Vught PW,  
Blauw HM, Franke L, Saris CG,  
Andersen PM, et al. ITPR2 as a 
susceptibility gene insporadic 
amyotrophic lateral sclerosis: A 
genome-wide asso-ciation study. Lancet 
Neurology. 2007;6:869-877
[10] DeJesus-Hernandez M, 
Mackenzie IR, Boeve BF, Boxer AL, 
Baker M, Rutherford NJ, et al. Expanded 
GGGGCC hexa-nucleotide repeat 
in noncoding region of C9ORF72 
causeschromosome 9p-linked FTD and 
ALS. Neuron. 2011;72:245-256
[11] Renton AE, Majounie E, Waite A, 
Simon-Sanchez J, Rollinson S, Gibbs JR, 
et al. A hexanucleotide repeat expansion 
in C9ORF72is the cause of chromosome 
9p21-linked ALS-FTD. Neuron. 
2011;72:257-268
[12] Thompson AG, Gray E, 
Thézénas ML, Charles PD, Evetts S,  
Hu MT, et al. Cerebrospinal fluid 
macrophage biomarkers in amyotrophic 
lateral sclerosis. Journal Annals of 
Neurology. 2018;83(2):258-268. DOI: 
10.1002/ana.25143. [Epub: 9 February 
2018]
[13] Sancho J, Servera E, Bañuls P, 
Marín J. Effectiveness of assisted 
and unassisted cough capacity in 
amyotrophic lateral sclerosis patients. 





[14] Allodi I, Nijssen J, Benitez JA, 
Schweingruber C, Fuchs A, Bonvicini G, 
et al. Modeling motor neuron resilience 
in ALS using stem cells. Stem Cell 
Reports. 2019;6711(19)30131-30136. 
DOI: 10.1016/j.stemcr.2019.04.009
[15] Edmond EC, Stagg CJ, Turner MR.  
Therapeutic non-invasive brain 
stimulation in amyotrophic lateral 
sclerosis: rationale, methods and 
Novel Aspects on Motor Neuron Disease
16
experience. The Journal of Neurology, 
Neurosurgery, and Psychiatry. 2019. 
pii: jnnp-2018-320213. DOI: 10.1136/
jnnp-2018-320213
[16] de Alcântara C, Cruzeiro MM,  
França MC Jr, Camargos ST, de 
Souza LC. Amyotrophic lateral sclerosis 
type 8 is not a pure motor disease: 
Evidence from a neuropsychological and 
behavioural study. Journal of Neurology. 
2019. DOI: 10.1007/s00415-019-09369-y
[17] Ando S, Funato M, Ohuchi K, 
Inagaki S, Sato A, Seki J, et al. The 
protective effects of Levetiracetam on a 
human iPSCs-derived spinal muscular 
atrophy model. Neurochemical 
Research. 2019. DOI: 10.1007/
s11064-019-02814-4
[18] Bozorg Qomi S, Asghari A, 
Salmaninejad A, Mojarrad M. Spinal 
muscular atrophy and common 
therapeutic advances. Fetal and 
Pediatric Pathology. 2019;38:1-13. DOI: 
10.1080/15513815.2018. 1520374
[19] Peikert K, Naumann M, Günther R,  
Wegner F, Hermann A. Off-label 
treatment of 4 amyotrophic lateral 
sclerosis patients with 4-Aminopyridine. 
Journal of Clinical Pharmacology. 2019. 
DOI: 10.1002/jcph.1437
[20] Neil EE, Bisaccia EK. Nusinersen: A 
novel antisense oligonucleotide for the 
treatment of spinal muscular atrophy. 
Journal of Pediatric Pharmacology and 
Therapeutics. 2019;24(3):194-203. DOI: 
10.5863/1551-6776-24.3.194
[21] Sugarman EA, Nagan N, Zhu H, 
et al. Pan-ethnic carrier screening and 
prenatal diagnosis for spinal muscular 
atrophy: Clinical laboratory analysis of 
>72,400 specimens. European Journal of 
Human Genetics. 2012;20:27-32
[22] Lunn MR, Wang CH. Spinal 
muscular atrophy. Lancet. 
2008;371:2120-2133
[23] Saffari A, Kölker S, Hoffmann GF, 
Weiler M, Ziegler A. Novel challenges 
in spinal muscular atrophy—How to 
screen and whom to treat? Annals 
of Clinical Translational Neurology. 
2019;6(1):197-205
[24] Finkel RS, Mercuri E, Darras BT, 
et al. Nusinersen versus sham control in 
infantile-onset spinal muscular atrophy. 
The New England Journal of Medicine. 
2017;377:1723-1732. [PubMed] [Google 
Scholar]
[25] Mercuri E, Darras BT, 
Chiriboga CA, et al. Nusinersen versus 
sham control in later-onset spinal 
muscular atrophy. The New England 
Journal of Medicine. 2018;378:625-635
[26] Bennett CF, Swayze EE. RNA 
targeting therapeutics: Molecular 
mechanisms of antisense 
oligonucleotides as a therapeutic 
platform. Annual Review of 
Pharmacology and Toxicology. 
2010;50:259-293
[27] Campbell MA, Wengel J. Locked vs. 
unlocked nucleic acids (LNA vs. UNA): 
Contrasting structures work towards 
common therapeutic goals. Chemical 
Society Reviews. 2011;40:5680-5689
[28] Elmén J, Thonberg H, Ljungberg K,  
et al. Locked nucleic acid (LNA) 
mediated improvements in siRNA 
stability and functionality. Nucleic 
Acids Research. 2005;33:439-447
[29] Mouawia H, Saker A, Jais JP, et al. 
Circulating trophoblastic cells provide 
genetic diagnosis in 63 fetuses at risk 
for cystic fibrosis or spinal muscular 
atrophy. Reproductive Biomedicine 
Online. 2012;25:508-520
[30] Parks M, Court S, Bowns B, et al. 
Non-invasive prenatal diagnosis of 
spinal muscular atrophy by relative 
haplotype dosage. European Journal of 
Human Genetics. 2017;25:416-422
17
Introduction to Novel Motor Neuron Disease
DOI: http://dx.doi.org/10.5772/intechopen.91921
[31] Bianchi DW, Chiu RWK. Sequencing 
of circulating cell-free DNA during 
pregnancy. The New England Journal of 
Medicine. 2018;379:464-473
[32] Iwamoto N, Butler DCD, 
Svrzikapa N, et al. Control of 
phosphorothioate stereochemistry 
substantially increases the efficacy 
of antisense oligonucleotides. Nature 
Biotechnology. 2017;35:845-851
[33] Wan WB, Migawa MT, Vasquez G, 
et al. Synthesis, biophysical properties 
and biological activity of second-
generation antisense oligonucleotides 
containing chiral phosphorothioate 
linkages. Nucleic Acids Research. 
2014;42:13456-13468
[34] Kaihatsu K, Janowski BA, Corey DR. 
Recognition of chromosomal DNA 
by PNAs. Chemistry & Biology. 
2004;11:749-758
[35] Stein CA. The experimental use of 
antisense oligonucleotides: A guide for 
the perplexed. The Journal of Clinical 
Investigation. 2001;108:641-644
[36] Krieg AM, Yi AK, Matson S, et al. 
CpG motifs in bacterial DNA trigger 
direct B-cell activation. Nature. 
1995;374:546-549
[37] Drygin D, Barone S, Bennett CF. 
Sequence-dependent cytotoxicity of 
second-generation oligonucleotides. 
Nucleic Acids Research. 
2004;32:6585-6594
[38] Aartsma-Rus A. FDA approval 
of nusinersen for spinal muscular 
atrophy makes 2016 the year of splice 
modulating oligonucleotides. Nucleic 
Acid Therapeutics. 2017;27:67-69
[39] Chiriboga CA, Swoboda KJ, 
Darras BT, et al. Results from a phase 1 
study of nusinersen (ISIS-SMN(Rx)) in 
children with spinal muscular atrophy. 
Neurology. 2016;86:890-897
[40] Luu KT, Norris DA, Gunawan R, 
et al. Population pharmacokinetics 
of nusinersen in the cerebral spinal 
fluid and plasma of pediatric patients 
with spinal muscular atrophy 
following intrathecal administrations. 
Journal of Clinical Pharmacology. 
2017;57:1031-1041
[41] Finkel RS, Chiriboga CA, Vajsar J, 
et al. Treatment of infantile-onset spinal 
muscular atrophy with nusinersen: A 
phase 2, open-label, dose-escalation 
study. Lancet. 2016;388:3017-3026
[42] Wurster CD, Winter B, Wollinsky K, 
Ludolph AC, Uzelac Z, Witzel S, et al. 
Intrathecal administration of nusinersen 
in adolescent and adult SMA type 2 
and 3 patients. Journal of Neurology. 
2019;266(1):183-194. DOI: 10.1007/
s00415-018-9124-0
[43] Sansone VA, Albamonte E, Salmin F, 
Casiraghi J, Pirola A, Bettinelli M, et al. 
Intrathecal nusinersen treatment for 
SMA in a dedicated neuromuscular 
clinic: An example of multidisciplinary 
and integrated care. Neurological 
Sciences. 2019;40(2):327-332. DOI: 
10.1007/s10072-018-3622-9
[44] Gidaro T, Servais L. Nusinersen 
treatment of spinal muscular atrophy: 
Current knowledge and existing gaps. 
Developmental Medicine and Child 
Neurology. 2019;61(1):19-24. DOI: 
10.1111/dmcn.14027
[45] Ortiz CB, Kukreja KU, Lotze TE, 
Chau A. Ultrasound-guided cervical 
puncture for nusinersen administration 
in adolescents. Pediatric Radiology. 
2019;49(1):136-140. DOI: 10.1007/
s00247-018-4240-7
[46] Scoles DR, Minikel EV, Pulst SM. 
Antisense oligonucleotides. Neurology: 
Genetics. 2019;5(2):e323. DOI: 10.1212/
NXG.0000000000000323
[47] van Roon-Mom WMC, Roos RAC, 
de Bot ST. Dose-dependent lowering 
Novel Aspects on Motor Neuron Disease
18
of mutant huntingtin using antisense 
oligonucleotides in Huntington disease 
patients. Nucleic Acid Therapeutics. 
2018;28:59-62
[48] McCampbell A, Cole T, Wegener AJ, 
et al. Antisense oligonucleotides extend 
survival and reverse decrement in 
muscle response in ALS models. The 
Journal of Clinical Investigation. 
2018;128:3558-3567
[49] Ly CV, Miller TM. Emerging 
antisense oligonucleotide and viral 
therapies for amyotrophic lateral 
sclerosis. Current Opinion in Neurology. 
2018;31:648-654
[50] DeVos SL, Goncharoff DK, 
Chen G, et al. Antisense reduction 
of tau in adult mice protects against 
seizures. The Journal of Neuroscience. 
2013;33:12887-12897
[51] Crooke ST, Wang S, Vickers TA, 
Shen W, Liang XH. Cellular uptake 
and trafficking of antisense 
oligonucleotides. Nature Biotechnology. 
2017;35:230-237
[52] Geary RS, Norris D, Yu R,  
Bennett CF. Pharmacokinetics, 
biodistribution and cell uptake of 
antisense oligonucleotides. Advanced 
Drug Delivery Reviews. 2015;87:46-51
[53] Klim JR, Vance C, Scotter EL. 
Antisense oligonucleotide therapies for 
amyotrophic lateral sclerosis: Existing 
and emerging targets. The International 
Journal of Biochemistry & Cell Biology. 
2019;110:149-153. DOI: 10.1016/ j.biocel. 
2019.03.009
[54] Bensimon G, Lacomblez L, 
Meininger V. A controlled trial 
of riluzole in amyotrophic lateral 
sclerosis. ALS/Riluzole study group. 
The New England Journal of Medicine. 
1994;330(9):585-591
[55] Dimitriadi M, Kye MJ, Kalloo G, 
Yersak JM, Sahin M, Hart AC. The 
neuroprotective drug riluzole acts via 
small conductance Ca2+-activated K+ 
channels to ameliorate defects in spinal 
muscular atrophy models. The Journal 
of Neuroscience. 2013;33(15):6557-6562. 
DOI: 10.1523/JNEUROSCI.1536-12.2013
[56] Brayfield A, editor. Martindale: 
The Complete Drug Reference. 37th ed. 
London, England, UK: Pharmaceutical 
Press; 2011. Available from https://
www.medicinescomplete.com 
[Accessed: 14 May 2019]
[57] NCBI (National Center for 
Biotechnology Information). PubChem 
Compound Database; CID = 5070 
(Riluzole) [webpage on the Internet]. 
Available from: https://pubchem.
ncbi.nlm.nih.gov/compound/
riluzole#section=Top [Accessed: 15 May 
2019]
[58] Hinchcliffe M, Smith A. Riluzole: 
Real-world evidence supports 
significant extension of median survival 
times in patients with amyotrophic 
lateral sclerosis. Degenerative 
Neurological and Neuromuscular 
Disease. 2017;7:61-70. DOI: 10.2147/
DNND.S135748
[59] Gaber TA-ZK, Mehmood Z, 
Siringwani H. Riluzole. Progress 
in Neurology and Psychiatry. 
2016;20:32-33
[60] NICE (National Institute for Clincal 
Excellence) (Technology Appraisal 
Guidance) TA20. Guidance on the Use of 
Riluzole (Rilutek) for the Treatment of 
Motor Neurone Disease. 2001. Available 
from: https://www.nice.org.uk/
Guidance/ta20 [Accessed: 19 May 2019]
[61] Dyer AM, Smith A. Riluzole 5 mg/
mL oral suspension: For optimized 
drug delivery in amyotrophic lateral 
sclerosis. Drug Design, Development 
and Therapy. 2017;11:59-64
[62] Keating GM. Riluzole oral 
suspension in amyotrophic lateral 
19
Introduction to Novel Motor Neuron Disease
DOI: http://dx.doi.org/10.5772/intechopen.91921
sclerosis: A guide to its use. 
Drugs & Therapy Perspectives. 
2016;32(7):282-286
[63] Ghaleiha A, Mohammadi E, 
Mohammadi M-R, et al. Riluzole as an 
adjunctive therapy to risperidone for 
the treatment of irritability in children 
with autistic disorder: A double-blind, 
placebo-controlled, randomized trial. 
Pediatric Drugs. 2013;15(6):505-514
[64] Rajasekaran S, Aiyer SN, 
Shetty AP, Kanna RM, Maheswaran A, 
Shetty JY. Effectiveness of riluzole as a 
pharmacotherapeutic treatment option 
for early cervical myelopathy: A double-
blinded, placebo-controlled randomised 
controlled trial. European Spine Journal. 
2016;25(6):1830-1835
[65] Farokhnia M, Sabzabadi M, 
Pourmahmoud H, et al. A double-
blind, placebo controlled, randomized 
trial of riluzole as an adjunct to ris-
peridone for treatment of negative 
symptoms in patients with chronic 
schizophrenia. Psychopharmacology. 
2014;231(3):533-542
[66] Brooks BR, Belden DS, Roelke K, 
et al. Survival in non-riluzole treated 
amyotrophic lateral sclerosis (ALS)—
Motor neuron disease (MND) patients 
with disease onset before and since 
1996 is identical: A clinic-based 
epidemiological study. Amyotrophic 
Lateral Sclerosis and Other Motor 
Neuron Disorders. 2001;2:60-61
[67] Turner MR, Bakker M, Sham P,  
Shaw CE, Leigh PN, Al-Chalabi A. 
Prognostic modelling of therapeutic 
interventions in amyotrophic lateral 
sclerosis. Amyotrophic Lateral Sclerosis 
and Other Motor Neuron Disorders. 
2002;3(1):15-21
[68] Mitchell JD, O’Brien MR, Joshi M. 
Audit of outcomes in motor neuron 
disease (MND) patients treated with 
riluzole. Amyotrophic Lateral Sclerosis. 
2006;7(2):67-71
[69] Zoccolella S, Beghi E, Palagano G,  
et al. SLAP registry Riluzole and 
amyotrophic lateral sclerosis survival: 
A population-based study in southern 
Italy. European Journal of Neurology. 
2007;14(3):262-268
[70] Lee CT-C, Chiu Y-W, Wang K-C, 
et al. Riluzole and prognostic factors 
in amyotrophic lateral sclerosis long-
term and short-term survival: A 
population-based study of 1149 cases 
in Taiwan. Journal of Epidemiology. 
2013;23(1):35-40
[71]  Georgoulopoulou E, Fini N, 
Vinceti M, et al. The impact of clinical 
factors, riluzole and therapeutic 
interventions on ALS survival: A 
population-based study in Modena, 
Italy. Amyotrophic Lateral Sclerosis 
and Frontotemporal Degeneration. 
2013;14(5-6):338-345 [PubMed] 
[Google Scholar]
[72] Knibb JA, Keren N, Kulka A, 
et al. A clinical tool for predicting 
survival in ALS. Journal of Neurology, 
Neurosurgery, and Psychiatry. 
2016;87(12):1361-1367
[73] Chen L, Liu X, Tang L, Zhang N, 
Fan D. Long-term use of riluzole could 
improve the prognosis of sporadic 
amyotrophic lateral sclerosis patients: 
A real-world cohort study in China. 
Frontiers in Aging Neuroscience. 
2016;8:246
[74] Inoue-Shibui A, Kato M, Suzuki N, 
Kobayashi J, Takai Y, Izumi R, et al. 
Interstitial pneumonia and other 
adverse events in riluzole-administered 
amyotrophic lateral sclerosis patients: A 
retrospective observational study. BMC 
Neurology. 2019;19:72
[75] Fang T, Al Khleifat A, Meurgey JH, 
Jones A, Leigh PN, Bensimon G, et al. 
Stage at which riluzole treatment 
prolongs survival in patients with 
amyotrophic lateral sclerosis: A 
retrospective analysis of data from 
Novel Aspects on Motor Neuron Disease
20
a dose-ranging study. The Lancet 
Neurology. 2018;17(5):416-422
[76] Falcão de Campos C, de Carvalho M. 
Riluzole-induced recurrent pancreatitis. 
Journal of Clinical Neuroscience. 
2017;45:153-154
[77] Jaiswal MK. Riluzole and edaravone: 
A tale of two amyotrophic lateral 
sclerosis drugs. Medicinal Research 
Reviews. 2019;39(2):733-748. DOI: 
10.1002/med.21528
[78] Ikeda K, Iwasaki Y. Edaravone, a free 
radical scavenger, delayed symptomatic 
and pathological progression of motor 
neuron disease in the wobbler mouse. 
PLoS One. 2015;10(10):e0140316. DOI: 
10.1371/journal.pone.0140316
[79] Lipman R, Kuskel R. Edaravone a 
novel neuroprotective agent. Journal 
of Neurology, Neurosurgery, and 
Psychiatry. 2017;89:144-151
[80] Writing Group; Edaravone (MCI-
186) ALS 19 Study Group. Safety and 
efficacy of edaravone in well defined 
patients with amyotrophic lateral 
sclerosis: A randomized, double-
blind, placebo-controlled trial. Lancet 
Neurology. 2017;16(7):505-512. DOI: 
10.1016/S1474-4422(17)30115-1
[81] Bhandari R, Kuhad A, Kuhad A. 
Edaravone: A new hope for deadly 
amyotrophic lateral sclerosis. Drugs 
of Today (Barcelona, Spain: 1998). 
2018;54(6):349-360. DOI: 10.1358/
dot.2018.54.6.2828189
[82] Yoshino H. Edaravone for 
the treatment of amyotrophic 
lateral sclerosis. Expert Review of 
Neurotherapeutics. 2019;19(3):185-193. 
DOI: 10.1080/14737175.2019.1581610
[83] Luo L, Song Z, Li X, Huiwang, 
Zeng Y, Qinwang, et al. Efficacy and 
safety of edaravone in treatment 
of amyotrophic lateral sclerosis-a 
systematic review and meta-analysis. 
Neurological Sciences. 2019;40(2):235-
241. DOI: 10.1007/s10072-018-3653-2
[84] de la Rubia JE, Drehmer E, 
Platero JL, Benlloch M, Caplliure-Llopis J, 
Villaron-Casales C, et al. Efficacy and 
tolerability of EH301 for amyotrophic 
lateral sclerosis: a randomized, double-
blind, placebo-controlled human pilot 
study. Amyotrophic Lateral Sclerosis 
and Frontotemporal Degeneration. 
2019;20(1-2):115-122. DOI: 
10.1080/21678421.2018.1536152
[85] Rando A, de la Torre M,  
Martinez-Muriana A, Zaragoza P,  
Musaro A, Hernández S, et al. 
Chemotherapeutic agent 5-fluorouracil 
increases survival of SOD1 mouse model 
of ALS. PLoS One. 2019;14(1):e0210752
[86] DuVal MG, Hinge VK, Snyder N, 
Kanyo R, Bratvold J, Pokrishevsky E, 
et al. Tryptophan 32 mediates SOD1 
toxicity in a in vivo motor neuron 
model of ALS and is a promising 
target for small molecule therapeutics. 
Neurobiology of Disease. 2019;124:297-
310. DOI: 10.1016/j.nbd.2018.11.025
[87] Paganoni S, Alshikho MJ, 
Luppino S, Chan J, Pothier L, 
Schoenfeld D, et al. A pilot trial of 
RNS60 in amyotrophic lateral sclerosis. 
Muscle & Nerve. 2019;59(3):303-308. 
DOI: 10.1002/mus.26385
[88] Wosiski-Kuhn M, Lyon MS, Caress J, 
Milligan C. Inflammation, immunity, 
and amyotrophic lateral sclerosis: 
II. Immune-modulating therapies. 
Muscle & Nerve. 2019;59(1):23-33. DOI: 
10.1002/mus.26288
[89] Shefner JM, Cudkowicz ME, 
Hardiman O, Cockroft BM, Lee JH,  
Malik FI, et al. A phase III trial 
of tirasemtiv as a potential 
treatment for amyotrophic lateral 
sclerosis. Amyotrophic Lateral 
Sclerosis and Frontotemporal 
Degeneration. 2019;27:1-9. DOI: 
10.1080/21678421.2019.1612922
21
Introduction to Novel Motor Neuron Disease
DOI: http://dx.doi.org/10.5772/intechopen.91921
[90] Zou S, Lan YL, Wang H, Zhang B,  
Sun YG. The potential roles of 
aquaporin 4 in amyotrophic lateral 
sclerosis. Neurological Sciences. 2019. 
DOI: 10.1007/s10072-019-03877-5
[91] Lingor P, Weber M, Camu W,  
Friede T, Hilgers R, Leha A, et al. 
Tolerability and efficacy of the Rho 
kinase (ROCK) inhibitor fasudil in 
amyotrophic lateral sclerosis. Frontiers 
in Neurology. 2019;10:293
[92] Koch J-C, Tatenhorst L,  
Roser AE, Saal KA, Tönges L, 
Lingor P. ROCK inhibition in models of 
neurodegeneration and its potential for 
clinical translation. Pharmacology & 
Therapeutics. 2018;189(C):1-21. DOI: 
10.1016/j.pharmthera.2018.03.008
[93] Conti A, Riva N, Pesca M, 
Iannaccone S, Cannistraci CV, Corbo M, 
et al. Increased expression of myosin 
binding protein H in the skeletal 
muscle of amyotrophic lateral sclerosis 
patients. Biochimica et Biophysica 
Acta. 2014;1842:99-106. DOI: 10.1016/j.
bbadis.2013.10.013
[94] Bedlack RS, Wicks P, Vaughan T, 
Opie A, Blum R, Dios A, et al. Lunasin 
does not slow ALS progression: Results 
of an open-label, single-center, hybrid-
virtual 12-month trial. Amyotrophic 
Lateral Sclerosis and Frontotemporal 
Degeneration. 2019;21:1-9. DOI: 
10.1080/21678421.2018.1556698

